Skip navigation
MedlinePlus Trusted Health Information for You U.S. National Library of MedicineNational Institutes of Health
Contact Us FAQs Site Map About MedlinePlus
español Home Health Topics Drugs & Supplements Medical Encyclopedia Dictionary News Directories Other Resources
Printer-friendly versionEmail this page to a friend

Factor XII (Hageman factor) deficiency

Factor XII deficiency is an inherited disorder that affects a protein (factor XII) involved in blood clotting.

Causes

When you bleed, the body launches a series of reactions that help the blood clot. This is called the coagulation cascade. The process involves special proteins called coagulation factors. (Factor XII is a coagulation factor in this series of reactions.)

Each factor has a reaction that triggers the next reaction. The final product of the coagulation cascade is the blood clot.

A lack of factor XII does not cause the affected person to bleed abnormally, but the blood takes longer than normal to clot in a test tube.

Factor XII deficiency is a rare inherited disorder.

Symptoms

There are usually no symptoms.

Exams and Tests

Factor XII deficiency is usually found when clotting tests are done for routine screening.

Tests may include:

Treatment

Treatment is generally unnecessary.

Outlook (Prognosis)

The outcome is expected to be good without treatment.

Possible Complications

There are usually no complications.

When to Contact a Medical Professional

This condition is usually discovered by the health care provider, when prolonged clotting is noticed in the process of running other laboratory tests.

Prevention

This is an inherited disorder. There is no known way to prevent it.

References

Kessler C. Hemorrhagic disorders: Coagulation factor deficiencies. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier;2007:chap 180.

Update Date: 3/2/2009

Updated by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.


A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2009, A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.


A.D.A.M. Logo